Last reviewed · How we verify
Burkitt cell leukemia
Approved treatments
- Mabthera · Roche
- Mabthera · Roche
Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC. - Mabthera · Roche
Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Burkitt cell leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Burkitt cell leukemia treatment landscape brief
- Burkitt cell leukemia treatment updates RSS
Frequently asked questions about Burkitt cell leukemia
What drugs treat Burkitt cell leukemia?
Tracked treatments include Mabthera.
What is the treatment for Burkitt cell leukemia?
Standard treatment for Burkitt cell leukemia includes Mabthera. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Burkitt cell leukemia patent cliff · Burkitt cell leukemia CI report
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- Treatment: Mabthera · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing